SUEMI MARUI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/25 - Laboratório de Endocrinologia Celular e Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/25 - Laboratório de Endocrinologia Celular e Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Rapid Control of T3 Thyrotoxicosis in Patients with Metastatic Follicular Thyroid Cancer Treated with Lenvatinib(2015) DANILOVIC, Debora Lucia Seguro; CAMARGO, Rosalinda Yossie Asato de; CASTRO JR., Gilberto; PAPADIA, Carla; MARUI, Suemi; HOFF, Ana Oliveira
bookPart Abordagem das tireoidopatias no idoso e TSH no envelhecimento(2015) BARROSO, Priscila Sales; MARUI, Suemi- Evaluation of Downstream Regulatory Element Antagonistic Modulator Gene in Human Multinodular Goiter(2015) SHINZATO, Amanda; LERARIO, Antonio M.; LIN, Chin J.; DANILOVIC, Debora S.; MARUI, Suemi; TRARBACH, Ericka B.Background: DREAM (Downstream Regulatory Element Antagonistic Modulator) is a neuronal calcium sensor that was suggested to modulate TSH receptor activity and whose overexpression provokes an enlargement of the thyroid gland in transgenic mice. The aim of this study was to investigate somatic mutations and DREAM gene expression in human multinodular goiter (MNG). Material/Methods: DNA and RNA samples were obtained from hyperplastic thyroid glands of 60 patients (54 females) with benign MNG. DREAM mutations were evaluated by PCR and direct automatic sequencing, whereas relative quantification of mRNA was performed by real-time PCR. Over-and under-expression were defined as a 2-fold increase and decrease in comparison to normal thyroid tissue, respectively. RQ M (relative quantification mean); SD (standard deviation). Results: DREAM expression was detected in all nodules evaluated. DREAM mRNA was overexpressed in 31.7% of MNG (RQ M=6.26; SD=5.08), whereas 53.3% and 15% had either normal (RQ M=1.16; SD=0.46) or underexpression (RQ M=0.30; SD=0.10), respectively. Regarding DREAM mutations analysis, only previously described intronic polymorphisms were observed. Conclusions: We report DREAM gene expression in the hyperplastic thyroid gland of MNG patients. However, DREAM expression did not vary significantly, and was somewhat underexpressed in most patients, suggesting that DREAM upregulation does not significantly affect nodular development in human goiter.